BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,629,171

« Back to Dashboard

Which drugs does patent 8,629,171 protect, and when does it expire?

Patent 8,629,171 protects DAKLINZA and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.

Summary for Patent: 8,629,171

Title:Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methy- lbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-me- thylpropyl)carbamate dihydrochloride salt
Abstract: The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-met- hylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2- -yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form.
Inventor(s): Kim; Soojin (Demarest, NJ), Gao; Qi (Wallingford, CT), Yang; Fukang (Madison, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:12/175,104
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bristol-myers SquibbDAKLINZAdaclatasvir dihydrochlorideTABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF INHIBITING HEPATITIS C VIRUS
Bristol-myers SquibbDAKLINZAdaclatasvir dihydrochlorideTABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF INHIBITING HEPATITIS C VIRUS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,629,171

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20100042641► Subscribe
Japan5244179► Subscribe
Japan2010535785► Subscribe
Israel203684► Subscribe
Hong Kong1144089► Subscribe
European Patent Office2183244► Subscribe
Spain2402791► Subscribe
Eurasian Patent Organization018152► Subscribe
Eurasian Patent Organization201000196► Subscribe
Colombia6160327► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: